表紙
市場調查報告書

未分化淋巴瘤激酶(ALK)抑制劑的全球市場:2020年-2024年

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 943477
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
未分化淋巴瘤激酶(ALK)抑制劑的全球市場:2020年-2024年 Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024
出版日期: 2020年06月09日內容資訊: 英文 120 Pages
簡介

未分化淋巴瘤激酶(ALK)抑制劑市場在2020年∼2024年間,預測將以20%的年複合成長率推移,並成長到29億6000萬美元的規模。

本報告提供未分化淋巴瘤激酶(ALK)抑制劑市場調查,提供市場概要,市場成長要素及阻礙因素分析,各類型·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各類型市場區隔

  • 市場·市場區隔
  • 各類型比較
  • 第2代ALK抑制劑-市場規模與預測(2019年-2024年)
  • 第1代ALK抑制劑-市場規模與預測(2019年-2024年)
  • 第3代ALK抑制劑-市場規模與預測(2019年-2024年)
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美 -市場規模與預測(2019年-2024年)
  • 歐洲-市場規模與預測(2019年-2024年)
  • 亞洲-市場規模與預測(2019年-2024年)
  • 其他地區-市場規模與預測(2019年-2024年)
  • 主要國家
  • 地區的市場機會
  • 成長要素-需求
  • 成長要素-外部要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概況
  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

附錄

目錄
Product Code: IRTNTR43929

Technavio has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period. Our reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors and high prevalence of lung cancer. In addition, high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

The anaplastic lymphoma kinase (ALK) inhibitors market analysis includes type segment and geographical landscapes

Technavio's ‘ anaplastic lymphoma kinase (ALK) inhibitors market ’ is segmented as below:

By Type:

  • Second-generation ALK inhibitors
  • First-generation ALK inhibitors
  • Third-generation ALK inhibitors

By Geography: landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas:

  • Anaplastic lymphoma kinase (ALK) inhibitors market sizing
  • Anaplastic lymphoma kinase (ALK) inhibitors market forecast
  • Anaplastic lymphoma kinase (ALK) inhibitors market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc.. Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Second-generation ALK inhibitors - Market size and forecast 2019-2024
  • First-generation ALK inhibitors - Market size and forecast 2019-2024
  • Third-generation ALK inhibitors - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Volume drivers - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Second-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Second-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: First-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 26: First-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 27: Third-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 28: Third-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Product and service
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: Betta Pharmaceuticals Co. Ltd. - Overview
  • 55: Betta Pharmaceuticals Co. Ltd. - Product and service
  • 56: Betta Pharmaceuticals Co. Ltd. - Key offerings
  • 57: Betta Pharmaceuticals Co. Ltd. - Key customers
  • 58: Betta Pharmaceuticals Co. Ltd. - Segment focus
  • 59: Bio-Techne Corp. - Overview
  • 60: Bio-Techne Corp. - Business segments
  • 61: Bio-Techne Corp. - Key offerings
  • 62: Bio-Techne Corp. - Key customers
  • 63: Bio-Techne Corp. - Segment focus
  • 64: F. Hoffmann-La Roche Ltd. - Overview
  • 65: F. Hoffmann-La Roche Ltd. - Business segments
  • 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • 67: F. Hoffmann-La Roche Ltd. - Key customers
  • 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • 69: GlaxoSmithKline Plc - Overview
  • 70: GlaxoSmithKline Plc - Business segments
  • 71: GlaxoSmithKline Plc - Key offerings
  • 72: GlaxoSmithKline Plc - Key customers
  • 73: GlaxoSmithKline Plc - Segment focus
  • 74: Merck KGaA - Overview
  • 75: Merck KGaA - Business segments
  • 76: Merck KGaA - Key offerings
  • 77: Merck KGaA - Key customers
  • 78: Merck KGaA - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: Turning Point Therapeutics Inc. - Overview
  • 95: Turning Point Therapeutics Inc. - Product and service
  • 96: Turning Point Therapeutics Inc. - Key offerings
  • 97: Turning Point Therapeutics Inc. - Key customers
  • 98: Turning Point Therapeutics Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations